Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $6 to $11.